Pinned Tweet
Thank you @ljmu @uhbtrust for helping me be become a biomedical scientist following a very successful and impressive verification today. @WeBMScientists @The_HCPC @IBMScience #biomedicalscientist #nhs
Victoria Hendry đź’™ retweeted
There is something hilarious about grown men treating a cardboard box and a carrot like high stakes espionage.
Sean barely has to break a sweat while Jon overanalyzes every facial expression, every pause, and every joke like his entire reputation is on the line. It shows how funny tension gets when the stakes are practically zero.
Half the fun is watching Sean casually cruise while Jon ties himself into knots trying to outsmart him.
Victoria Hendry đź’™ retweeted
"He told me that I played very well" 🤝
Zion Suzuki reveals what Alisson said after Japan played Brazil at the World Cup 🗣️
Victoria Hendry đź’™ retweeted
Whenever a celebrity PR apology starts with "my accountant said it's totally legal," you already know the punchlines are lining themselves up.
Sean Lock doesn't even let Jimmy Carr get a real defense in he just paints a vivid prison visiting room picture of thick glass, a boiler suit, and a brutal haircut.
It's funny because the whole premise mocks how convenient "somebody told me it was fine" sounds once the headlines hit.
Victoria Hendry đź’™ retweeted
Online now: XPO5 regulates ferroptosis via MITF-ACSL4 signaling to drive CRPC progression and serves as a druggable target dlvr.​it/TWQTh2
Victoria Hendry đź’™ retweeted
What do 42 types of cancer have in common?
Their TME pattern @NatureNV
nature.com/articles/d41586-0…
The tumor microenvironment (TME) is pivotal to cancer growth, metastasis, and successful intervention. Our TME knowledge advanced here by 42 cancer types, 15 million cells, in humans and mice @nature open-access
nature.com/articles/s41586-0…
Victoria Hendry đź’™ retweeted
Pancreatic cancer cells express cryptic peptides shared across patients that may be therapeutic targets, according to a 2025 study in Science.
Learn more in this #SciencePerspective on #WorldPancreaticCancerDay: scim.ag/4kkI7vD
Victoria Hendry đź’™ retweeted
Microbiome-derived phenylethylamine impairs diabetic wound healing via TAAR1-mediated NETosis dlvr.​it/TWQ7LX
Victoria Hendry đź’™ retweeted
.@UniAvogadro Researchers indicate that shifting the immune response toward a robust M1/Th1 state can significantly improve current #immunotherapies and #chemotherapies, by limiting cancer stem cell properties.
Read their @CIR_AACR paper đź“‘ bit.ly/4tbnlkt
An analysis of 42 cancer types reveals shared patterns of gene activity in the tumour microenvironment, which might point to treatments that work across a range of cancers
go.nature.com/3WVrwVB
Victoria Hendry đź’™ retweeted
🧬 Is the tumor microenvironment more conserved than the tumors themselves?
Fascinating new study in @Nature!
Across 42 cancer types and >2,000 human & mouse tumor samples, Januszyk et al. identify conserved stromal and immune transcriptional programs across organs and species.
An exciting step towards understanding shared mechanisms of immune evasion and therapy resistance.
Could pan-cancer TME signatures help us develop better biomarkers for immunotherapy—even across different tumor entities?
Importantly, shared transcriptional programs ≠identical therapeutic vulnerabilities.
🔗 doi.org/10.1038/s41586-026-1…
Explore the atlas: tmeatlas.stanford.edu
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Victoria Hendry đź’™ retweeted
We've never known more about cancer. Yet many of the biggest questions remain unanswered.
This thoughtful @FinancialTimes article explores both realities: the breakthroughs changing lives today, and the unanswered questions that will define the next generation of cancer research.
Meeting those challenges will require the kind of bold, collaborative science that Cancer Grand Challenges exists to support.
Great to see insights from members of the Cancer Grand Challenges community, including @AndyChanMD from team PROSPECT and Scientific Committee member Karen Vousden, featured in this piece.
Read more ➡️ bit.ly/48qevWG
Victoria Hendry đź’™ retweeted
Designer mucin-responsive nanomedicine for enhanced solid tumour penetration and therapy go.​nature.​com/3WD0kuK
Victoria Hendry đź’™ retweeted
A therapeutic sweet spot between efficacy and safety: doi.org/10.1172/JCI204657
Shijie Li @ivimmoun et al. @Tsinghua_Uni report on a new T cell engager (TCE) that uses tumor-controlled IL-2 signaling to enhance #CancerTreatment while reducing toxicity. In preclinical models, the protease-activatable TCE elicited potent antitumor activity, mitigated T cell exhaustion, and minimized systemic cytokine release.
Victoria Hendry đź’™ retweeted
WSTF phosphorylates AKT1 to promote PI3K-dependent AKT activation and tumorigenesis dlvr.​it/TWNkB3
Victoria Hendry đź’™ retweeted
The tumor microenvironment (TME) is pivotal to cancer growth, metastasis, and successful intervention. Our TME knowledge advanced here by 42 cancer types, 15 million cells, in humans and mice @nature open-access
nature.com/articles/s41586-0…
Victoria Hendry đź’™ retweeted
Tumours may grow new blood vessels not only by pressing the accelerator, but by cutting the brakes. New study identifies mechanism that shuts down the pericyte suppressor Kai1/CD82, promoting VEGF-independent angiogenesis and tumour growth nature.com/articles/s41388-0…
Victoria Hendry đź’™ retweeted
CCNE1 Amplification Confers Poor Outcomes and Therapeutic Resistance in Breast Cancer

Clinical Cancer Research, online November 17, 2026 · Antonio Marra (European Institute of Oncology) … Sarat Chandarlapaty, Pedram Razavi and Ezra Y. Rosen (Memorial Sloan Kettering), with Britta Weigelt and Jorge Reis-Filho · Therapy resistance / new therapy targets
AI summary reviewed and approved by Dr. El-Deiry:

“CCNE1 amplification is established as a driver and a poor-prognosis marker in ovarian and gastric cancer; establishing its weight in breast cancer matters now rather than five years ago because of what is in development against it. Cyclin E1 overexpression drives CDK2-dependent proliferation that bypasses CDK4/6 inhibition, which is the dominant first-line backbone in ER-positive disease, and selective CDK2 inhibitors are in trials specifically for this dependency. If the amplification is both prognostic and predictive of resistance, it becomes a testable reason to sequence a CDK2 agent rather than cycling endocrine therapy. From the MSK group that has done much of the genomic work on endocrine resistance. Ahead-of-print and summarized from the record; whether the resistance is specific to CDK4/6 inhibition or reflects general aggressiveness is the distinction the full text needs to make.”
doi.org/10.1158/1078-0432.CC…
Victoria Hendry đź’™ retweeted
Tuning the immune ecosystem to treat cancer
Engineering the immune cell milieu around tumors could make them more sensitive to immunotherapy
science.org/doi/10.1126/scie…
Victoria Hendry đź’™ retweeted
CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma.
Research from @nicole_scheff @Pitt_Brain & colleagues in @CellReports #SfN26 hubs.li/Q04Ft6yf0
Victoria Hendry đź’™ retweeted
RESEARCH SPOTLIGHT🔦Asmaa El-Kenawi, PharmD, research is uncovering new insights into prostate cancer and potential paths to better treatment. Read more about @asmaakenawy!
medicine.iu.edu/blogs/resear…


























